Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (Form: SC 13G/A, Received: 02/07/2018 16:21:47)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*
 
Esperion Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
29664W-10-5
(CUSIP Number)
 
December 31, 2017
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
  o
Rule 13d-1(b)
  o
Rule 13d-1(c)
  x
Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 



 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 2 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Aisling Capital II, LP
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
PN
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 3 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Aisling Capital Partners, LP
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
PN
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 4 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Aisling Capital Partners, LLC
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
OO
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 5 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Steve Elms
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
IN
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 6 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Dennis Purcell
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
IN
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 7 of 12
 
 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Andrew Schiff
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)   o
(b)  x
3
SEC USE ONLY
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
 
NUMBER OF
SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0 (See Item 4)
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
 
12
TYPE OF REPORTING PERSON
 
IN
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 8 of 12
 
 
ITEM 1.
(a)
Name of Issuer:
     
   
Esperion Therapeutics, Inc. (the “Issuer”)
     
 
(b)
Address of Issuer’s Principal Executive Offices:
     
   
3891 Ranchero Drive, Suite 150
Ann Arbor, MI 48108
   
ITEM 2.
(a)
Name of Person Filing:
     
   
This Schedule 13G (this “Statement”) is being filed by the following persons (collectively, the “Reporting Persons”):
 
     
(i)
Aisling Capital II, LP, a Delaware limited partnership (“Aisling”);
     
(ii)
Aisling Capital Partners, LP, a Delaware limited partnership (“Aisling Partners” and a general partner of Aisling);
     
(iii)
Aisling Capital Partners LLC, a Delaware limited liability company (“Aisling Partners GP” and a general partner of Aisling Partners);
     
(iv)
Mr. Steve Elms (“Mr. Elms” and a managing member of Aisling Partners GP);
     
(v)
Mr. Dennis Purcell (“Mr. Purcell” and a managing member of Aisling Partners GP); and
     
(vi)
Mr. Andrew Schiff (“Mr. Schiff” and a managing member of Aisling Partners GP).

 
(b)
Address of Principal Business Office, or if None, Residence:
     
   
The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 12th Floor, New York, New York 10106.
     
 
(c)
Citizenship:

     
(i)
Aisling — a Delaware limited partnership
     
(ii)
Aisling Partners — a Delaware limited partnership
     
(iii)
Aisling Partners GP — a Delaware limited liability company
     
(iv)
Mr. Elms — United States
     
(v)
Mr. Purcell — United States
     
(vi)
Mr. Schiff — United States

 
(d)
Title of Class of Securities:
     
   
Common Stock, par value $0.001 per share (the “Common Stock”).
     
 
(e)
CUSIP Number:
     
   
29664W-10-5
     
ITEM 3.
IF THIS STATEMENT IS FILED PURSUANT TO § 240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
     
 
(a)
[__]  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
 
(b)
[__]  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
 
(c)
[__]  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)
 
(d)
[__]  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
 
(e)
[__]  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)
 
(f)
[__]  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 9 of 12
 
 
 
(g)
[__]  A Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
(h)
[__]  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
 
(i)
[__]  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
 
(j)
[__]  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
(k)
[__]  Group, in accordance with §240.13d-1(b)(1)(ii)(J).
   
ITEM 4.
OWNERSHIP
   
 
(a)
Amount beneficially owned:
     
   
Each of the Reporting Persons may be deemed to beneficially own an aggregate of 0 shares of Common Stock.
     
 
(b)
Percent of class:
     
   
Based on the calculations made in accordance with Rule 13d-3(d), each of the Reporting Persons may be deemed to beneficially own approximately 0.0% of the outstanding Common Stock.
     
 
(c)
Number of shares as to which such person has:
     
   
(i), (iii)
Sole power to vote or to direct the vote
       
     
Each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of 0 shares of Common Stock beneficially owned by Aisling.
       
   
(ii), (iv)
Shared power to vote or to direct the vote
       
     
By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of Mr. Elms, Mr. Purcell and Mr. Schiff may be deemed to share the power to direct the voting and the disposition of 0 shares of Common Stock beneficially owned by Aisling.
 
ITEM 5.
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
 
Not Applicable.
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☑.
   
ITEM 6.
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
 
The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Shares held for the account of Aisling in accordance with their ownership interests in Aisling.
   
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 10 of 12
 
 
ITEM 7.
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
 
 
Not Applicable.
   
ITEM 8.
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
 
 
Not Applicable.
   
ITEM 9.
NOTICE OF DISSOLUTION OF GROUP
 
 
Not Applicable.
   
ITEM 10.
CERTIFICATIONS.
 
 
Not Applicable.
 
 
 
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 11 of 12


SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  February 7, 2018


 
AISLING CAPITAL II, LP
 
By: Aisling Capital Partners, LP,
As its General Partner
 
By: Aisling Capital Partners, LLC,
As its General Partner
 
By: 
 
 
/s/  Robert Wenzel
   
Name:  Robert Wenzel
Title:   Chief Financial Officer

 
AISLING CAPITAL PARTNERS, LP
 
By: Aisling Capital Partners, LLC,
As its General Partner
 
By: 
 
 
/s/  Robert Wenzel
   
Name:  Robert Wenzel
Title:   Chief Financial Officer

 
AISLING CAPITAL PARTNERS, LLC
 
By: 
 
 
/s/  Robert Wenzel
   
Name:  Robert Wenzel
Title:   Chief Financial Officer

 
STEVE ELMS
 
By: 
 
 
/s/  Steve Elms
 

 
CUSIP No. 29664W-10-5
SCHEDULE 13G
Page 12 of 12
 
 
 
DENNIS PURCELL
 
By: 
 
 
/s/  Dennis Purcell

 
ANDREW SCHIFF
 
By: 
 
 
/s/  Andrew Schiff
 
 
 
 
 
 
 

 
EXHIBIT INDEX
 
Exhibit 1.
Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed).